NW Bio Registers $4.9M Yorkville Convertible Note at $0.16/Share
NWBO sits 16% above its 52-week low of $0.141 on light trading volume (0.4× avg).
Summary
NW Bio registers a new $4.9M convertible note with Yorkville, issuing shares at $0.16 and warrants at $0.205 — dilutive survival financing for a cash-strapped biotech.
Key Events · Financing and Capital Events · NWBO
-
$4.9M Convertible Note with Yorkville
A $4.9 million convertible promissory note was entered into with YA II PN, Ltd. (Yorkville) on July 29, 2026. The note matures in 12 months, carries a 5% OID, no interest, and converts at a small discount to market.
-
40.3M Shares Registered for Conversion & Warrants
The registration covers 30,625,000 shares for note conversion at an assumed $0.16 per share, and 9,700,000 warrant shares exercisable at $0.205 per share for three years. Actual conversion shares may vary with market price.
-
Net Proceeds of $4.655M
After original issue discount and fees, the company receives approximately $4.655 million, intended for working capital, manufacturing expansion, and clinical trials.
-
Dilution and Overhang
The 40.3 million shares represent about 2.4% of the current 1.69 billion outstanding shares, but the note's variable conversion price and warrants add ongoing dilution risk. The company already has a going-concern warning and negative tangible book value.
Analysis · NWBO · Life Sciences
On July 29, 2026, Northwest Biotherapeutics entered a $4.9 million convertible note with YA II PN, Ltd. (Yorkville) and is registering 40.3 million shares to cover potential conversions and warrants. The note converts at a small discount to market, with an assumed price of $0.16 — right at the current $0.164 stock price. Net proceeds are $4.655 million after fees. This is dilutive survival financing for a company already under a going-concern warning and burning cash. The deal includes 9.7 million warrant shares at $0.205, adding further overhang. While the cash extends the runway, the structure — a convertible note with a discount and warrants — is typical of distressed biotech funding and will pressure the stock.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NWBO was trading at $0.16 on OTC in the Life Sciences sector, with a market capitalization of approximately $276.8M. The 52-week trading range was $0.14 to $0.37. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.